15 New Messages
Digest #20069
2a
Re: Pasien berobat ke alternatif, tidak sembuh malah bertambah parah by "Shinta Oktaviana" vian199
Messages
Tks a lot dr Wati. SOL.
Rgds,
Marcella
*maaf gak potek
Sent from my BlackBerry®
powered by Sinyal Kuat INDOSAT
-----Original Message-----
From: "Hen" <hendriyati.s@gmail.com >
Sender: sehat@yahoogroups.com
Date: Tue, 4 Jun 2013 04:36:17
To: <sehat@yahoogroups.com >
Reply-To: sehat@yahoogroups.com
Subject: Re: [sehat] dr ahli paru untuk anak
Kalau pneumonia sih gak usah dsa paru
Btw, dsa paru di jak:
Noenoeng rahayu
Nastiti rahayu
Budiman
Mardjanis
Bambang S
Darmawan
Nastiti
HenB
[Non-text portions of this message have been removed]
Rgds,
Marcella
*maaf gak potek
Sent from my BlackBerry®
powered by Sinyal Kuat INDOSAT
-----Original Message-----
From: "Hen" <hendriyati.s@
Sender: sehat@yahoogroups.
Date: Tue, 4 Jun 2013 04:36:17
To: <sehat@yahoogroups.
Reply-To: sehat@yahoogroups.
Subject: Re: [sehat] dr ahli paru untuk anak
Kalau pneumonia sih gak usah dsa paru
Btw, dsa paru di jak:
Noenoeng rahayu
Nastiti rahayu
Budiman
Mardjanis
Bambang S
Darmawan
Nastiti
HenB
[Non-text portions of this message have been removed]
Mon Jun 3, 2013 10:09 pm (PDT) . Posted by:
"Shinta Oktaviana" vian199
setuju dgn mba putri :)
>
> Saat menjalani pengobatan2 alternatif, sangat mungkin, bahkan hampir pasti
> tdk rasional, tapi spirit of life-nya ibu jadi ada. Entah karena sugesti,
> ato kemampuan "sang terapis" berkomunikasi shg ibu bs nyaman dgn kankernya,
> bisa menerima kesakitan parahnya lebih ikhlas, lebih tenang, tanpa
> ketakutan berlebih (krn dulu ibu bahkan lewat RS beliau pernah dikemo
> langsung panic attack, padahal cuma lewat aja).
>
keluarga saya dari kecil pengguna fasilitas kesehatan rakyat, dari jatah
askes yg kelas 3, sampe sekarang alhamdulillah jatah askes ortu saya udah
bs dpt kamar kelas 1.
jadi merasakan sekali kurangnya sisi "humanis" tenaga medis pemerintah
dalam mengadapi org yg lagi sakit, baik pasien maupun keluarganya.
berbeda dengan cara tenaga medis di rumah sakti swasta.
walopun saat ini justru saya bersyukur dr dulu berobatnya di puskes dan
rsud :)
tapi, makin kesini saya makin salut dengan tenaga medis pemerintah..
3 thn lalu, menemani papa di UGD di RSUD daerah, cuma ada 1 dokter jaga,
sementara yg masuk UGD banyak. udah SDM gak ada alat gak ada...
tadinya pengen diskusi detail dgn dokter jaga, tp langsung sadar diri...
dokter juga manusia...
ketika kita menuntut dokter untuk RUM, kita juga harus mau belajar jadi
ortu yg RUM..
salam
~Shinta
[Non-text portions of this message have been removed]
>
> Saat menjalani pengobatan2 alternatif, sangat mungkin, bahkan hampir pasti
> tdk rasional, tapi spirit of life-nya ibu jadi ada. Entah karena sugesti,
> ato kemampuan "sang terapis" berkomunikasi shg ibu bs nyaman dgn kankernya,
> bisa menerima kesakitan parahnya lebih ikhlas, lebih tenang, tanpa
> ketakutan berlebih (krn dulu ibu bahkan lewat RS beliau pernah dikemo
> langsung panic attack, padahal cuma lewat aja).
>
keluarga saya dari kecil pengguna fasilitas kesehatan rakyat, dari jatah
askes yg kelas 3, sampe sekarang alhamdulillah jatah askes ortu saya udah
bs dpt kamar kelas 1.
jadi merasakan sekali kurangnya sisi "humanis" tenaga medis pemerintah
dalam mengadapi org yg lagi sakit, baik pasien maupun keluarganya.
berbeda dengan cara tenaga medis di rumah sakti swasta.
walopun saat ini justru saya bersyukur dr dulu berobatnya di puskes dan
rsud :)
tapi, makin kesini saya makin salut dengan tenaga medis pemerintah..
3 thn lalu, menemani papa di UGD di RSUD daerah, cuma ada 1 dokter jaga,
sementara yg masuk UGD banyak. udah SDM gak ada alat gak ada...
tadinya pengen diskusi detail dgn dokter jaga, tp langsung sadar diri...
dokter juga manusia...
ketika kita menuntut dokter untuk RUM, kita juga harus mau belajar jadi
ortu yg RUM..
salam
~Shinta
[Non-text portions of this message have been removed]
Mon Jun 3, 2013 11:22 pm (PDT) . Posted by:
"IntanAriestya" intanariestya
Dear docs and SPs,
Hanya ingin berucap syukur alhamdulillah, PESAT SUA Bandung sdh terlaksana tgl 1-2 Juni 2013. Peserta melebihi target, datang dari yg dekat sampe yg jauh, antusias dan bertanya bertubi-tubi bikin bunda, dr Apin dan mbak Manik La Luna harus menunda lunch yg sdh terhidang. Padahal udah laper yaa? Hehe..
Terimakasih yg takterkira untuk tim panitia yg hebat luar biasa, mbak winny, mbak endah, mbak biqies, mbak dewi ck, mbak rilly, mbak siska dan last but not least pak yan. Ga lupa buat suami2 siaga dan anak2 kooperatif. Semoga ini adalah ladang amal dan pahala utk kita semua. Ribet, riweuh, rempong sana sini, tapi hepi dan haha hihi all the time kan ya? Tengkyu, semoga kita bersaudara sampe tua. Aamiin.
Terimakasih untuk bunda Wati, mbak Vida, dr Apin, dan mbak Patty. Terimakasih untuk mbak Manik La Luna sudah ngemsi dgn keren, dan bonus cilok colak colek bwt panitia. Terimakasih utk para sponsor, Hansaplast, Amidis air mineral, RM Ponyo, dMimo house, minime photobooth, bradford cafe, dan majalah parenting sebagai media partner.
Terimakasih utk relawan SUA Bandung, skrg sdh punya koordinator baru.. (Hai mbak Andi Fitri) semoga visi misi kita utk kampanye AB yg bijak rasional trs berjalan dan makin banyak keluarga yg tercerahkan.
Terimakasih semua, mohon maaf atas keterbatasan sy pribadi maupun panitia selama acara. Sampai ketemu lg di PESAT Bandung berikutnya.. (Soon yaa, Bunda? Hehe)
*eh, kok panjang yaa?*
Salam,
IntanAriestya || @intanariestya
Tim KLASI YOP Bandung
*Breastfeeding: Stop judging, Start supporting*
Hanya ingin berucap syukur alhamdulillah, PESAT SUA Bandung sdh terlaksana tgl 1-2 Juni 2013. Peserta melebihi target, datang dari yg dekat sampe yg jauh, antusias dan bertanya bertubi-tubi bikin bunda, dr Apin dan mbak Manik La Luna harus menunda lunch yg sdh terhidang. Padahal udah laper yaa? Hehe..
Terimakasih yg takterkira untuk tim panitia yg hebat luar biasa, mbak winny, mbak endah, mbak biqies, mbak dewi ck, mbak rilly, mbak siska dan last but not least pak yan. Ga lupa buat suami2 siaga dan anak2 kooperatif. Semoga ini adalah ladang amal dan pahala utk kita semua. Ribet, riweuh, rempong sana sini, tapi hepi dan haha hihi all the time kan ya? Tengkyu, semoga kita bersaudara sampe tua. Aamiin.
Terimakasih untuk bunda Wati, mbak Vida, dr Apin, dan mbak Patty. Terimakasih untuk mbak Manik La Luna sudah ngemsi dgn keren, dan bonus cilok colak colek bwt panitia. Terimakasih utk para sponsor, Hansaplast, Amidis air mineral, RM Ponyo, dMimo house, minime photobooth, bradford cafe, dan majalah parenting sebagai media partner.
Terimakasih utk relawan SUA Bandung, skrg sdh punya koordinator baru.. (Hai mbak Andi Fitri) semoga visi misi kita utk kampanye AB yg bijak rasional trs berjalan dan makin banyak keluarga yg tercerahkan.
Terimakasih semua, mohon maaf atas keterbatasan sy pribadi maupun panitia selama acara. Sampai ketemu lg di PESAT Bandung berikutnya.. (Soon yaa, Bunda? Hehe)
*eh, kok panjang yaa?*
Salam,
IntanAriestya || @intanariestya
Tim KLASI YOP Bandung
*Breastfeeding: Stop judging, Start supporting*
Mon Jun 3, 2013 11:40 pm (PDT) . Posted by:
"Sylvia Sumargi" sylviasumargi
Bravo Bandung! Maju terus!
Selamat berkarya para relawan Bandung!
[Non-text portions of this message have been removed]
Selamat berkarya para relawan Bandung!
[Non-text portions of this message have been removed]
Mon Jun 3, 2013 11:23 pm (PDT) . Posted by:
"/Ghozan"
fyi
quote :
The effectiveness and safety of newly developed drugs are often viewed
too optimistically.^1
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R1 > ^,
^2 <http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R2 >
According to a Cochrane systematic review published recently, new drugs
are seldom found to be substantially better than existing treatments.^3
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R3 >
However, because of lack of full and transparent access to the protocols
of many clinical trials, compounded by publication bias and selective
reporting of their findings, the true effectiveness of many drugs
remains unknown. It is a fact that the results of trials are more likely
to be published if the findings are favourable than if they are not.^4
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R4 > I
Independent drug bulletins to promote the prescription of appropriate
drugs: a necessary but difficult task
Bernard Burnand ^a
a. Institute of Social and Preventive Medicine, Lausanne University
Hospital, 10 route de la Corniche, 1010 Lausanne, Switzerland.
Correspondence to Bernard Burnand (e-mail: Bernard.Burnand@chuv.ch
<mailto:Bernard.Burnand@chuv.ch >).
/Bulletin of the World Health Organization/ 2013;91:391-391A. doi:
http://dx.doi.org/10.2471/BLT.13.122762
Drug treatments constitute a substantial portion of all health-care
interventions. Despite their notable benefits, however, drug treatments
are beyond the reach of sizable population groups and in some parts of
the world there is little access to safe and effective medications even
though new drugs are constantly being developed.
The effectiveness and safety of newly developed drugs are often viewed
too optimistically.^1
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R1 > ^,
^2 <http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R2 >
According to a Cochrane systematic review published recently, new drugs
are seldom found to be substantially better than existing treatments.^3
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R3 >
However, because of lack of full and transparent access to the protocols
of many clinical trials, compounded by publication bias and selective
reporting of their findings, the true effectiveness of many drugs
remains unknown. It is a fact that the results of trials are more likely
to be published if the findings are favourable than if they are not.^4
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R4 > In
addition, some measured outcomes are never reported,^5
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R5 >
which generally results in an overestimation of effectiveness and an
underestimation of harmful effects. Thus, researchers and the public
only come to know about those findings that are published and disclosed,
and physicians prescribe treatments on the basis of this biased
information. For all of these reasons, it is critically important that
prescribing physicians have a source of information about drug
effectiveness that is independent and as objective as possible.
Truly independent drug bulletins -- those produced without financial or
editorial intervention from the pharmaceutical industry, regulatory
agencies and governments -- are such a source.^6
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R6 >
They make a contribution to society by objectively comparing the
effectiveness of different drugs. Independent drug bulletins began to
appear in the 1960s, after the thalidomide scandal. At the time the
pharmaceutical industry was producing new drugs that were modifying
health-care practices. In the 1970s, a group of physicians and
pharmacists in France began to meet to discuss and prepare independent
information about drugs for other physicians and pharmacists. The group,
which came to be known as "Prescrire", gained official recognition in
1980, when the French Minister of Health commissioned it to provide
independent information to the drug authorities. The group was initially
supported through government funding, but this was eventually suspended
and its drug bulletin, /Prescrire/, has been fully independent since
1993.^7
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R7 >
/Prescire/ is an example of a truly independent drug bulletin. It
publishes no advertisements and is financed solely through subscriptions
and training courses for health-care professionals. Its readership,
mainly physicians and pharmacists living in France, grew gradually until
2000, plateaued for several years, and jumped to about 35 000 in 2012
after the European Medicines Agency recommended the withdrawal of
benfluorex.^8
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R8 >
/Prescrire/ is published in French, although some reports are available
in English.
/Prescrire/'s articles and reports are the result of close collaboration
among physicians and pharmacists. They are prepared by about 100 paid
collaborators trained in the use of evidence-based approaches and have
no individual authors. This 80-page, entertaining monthly bulletin
contains reports, news and practical guidance. Each report is written by
a main author and a co-author, who together conduct an exhaustive,
systematic search of the information available on a given drug (i.e.
published articles, reviews and guidelines, agency reports, reports
obtained from pharmaceutical companies) and prepare a critical
appraisal. After the co-authors and the editor in charge have reached
agreement on a final draft, every report is reviewed by 15 to 40
internal and external peers before being revised and finalized by the
authors and the bulletin's editorial committee. Additional reports,
including the annual financial statement, are available on the
bulletin's web site. /Prescrire/ is influential in official drug-related
decisions and daily drug use in France.
There is a definite place for independent drug bulletins.^6
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R6 >
The International Society of Drug Bulletins lists 50 of these
publications, mainly from Europe and South America.^9
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R9 >
Regardless of the difficulty of relying solely on subscriptions to pay
for the collaborators' hard work, the model merits being widely
reproduced. Yet despite their vital role, independent drug bulletins
cannot begin to compensate for the lack of transparency in the reporting
of clinical research.^10
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R10 >
Of all the clinical trials that are conducted, only about half publish
their results and those that yield positive findings are selectively
published more often.^11
<http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html#R11 >
This is inadmissible. Everything from the key components of the protocol
to the full data set must be made available for public scrutiny. To
achieve this goal, authorities as well as national and international
agencies must be persuaded, through strong and persistent advocacy, to
adopt and enforce measures mandating the transparency of the entire
clinical research process.
----------------------------------------------------------
Acknowledgements
The author thanks Pierre Chirac of "Prescrire" for the information he
provided.
References
* Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R.
Selective publication of antidepressant trials and its influence on
apparent efficacy. /N Engl J Med/ 2008; 358: 252-60
http://dx.doi.org/10.1056/NEJMsa065779 pmid: 18199864
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=18199864&dopt=Abstract >.
* Rising K, Bacchetti P, Bero L. Reporting bias in drug trials
submitted to the Food and Drug Administration: review of publication
and presentation. /PLoS Med/ 2008; 5: e217, discussion e217
http://dx.doi.org/10.1371/journal.pmed.0050217 pmid: 19067477
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=19067477&dopt=Abstract >.
* Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, et
al., et al. New treatments compared to established treatments in
randomized trials. /Cochrane Database Syst Rev/ 2012; 10: MR000024
http://dx.doi.org/10.1002/14651858 pmid: 23076962
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=23076962&dopt=Abstract >.
* Gøtzsche PC. Why we need easy access to all data from all clinical
trials and how to accomplish it. /Trials/ 2011; 12: 249
http://dx.doi.org/10.1186/1745-6215-12-249 pmid: 22112900
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=22112900&dopt=Abstract >.
* Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in
industry-sponsored trials of gabapentin for off-label use. /N Engl J
Med/ 2009; 361: 1963-71 http://dx.doi.org/10.1056/NEJMsa0906126
pmid: 19907043
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=19907043&dopt=Abstract >.
* The future of independent drug bulletins. /Drug Ther Bull/ 2012; 50:
61 http://dx.doi.org/10.1136/dtb.2012.06.0106 pmid: 22679242
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=22679242&dopt=Abstract >.
* Prescrire.org [Internet]. /Prescrire./ Paris: Prescrire; 2013.
Available from: http://www.prescrire.org/fr/ [accessed 25 April 2013].
* Mullard A. Mediator scandal rocks French medical community. /Lancet/
2011; 377: 890-2 http://dx.doi.org/10.1016/S0140-6736 (11)60334-6
<http://dx.doi.org/10.1016/S0140-6736%2811%2960334-6 > pmid: 21409784
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=21409784&dopt=Abstract >.
* ISDB [Internet]. Paris: International Society of Drug Bulletins;
2013. Available from: www.isdbweb.org <http://www.isdbweb.org >
[accessed 25 April 2013].
* Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical
trials. /BMJ/ 2012; 345: e8522 http://dx.doi.org/10.1136/bmj.e8522
pmid: 23258926
<http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=23258926&dopt=Abstract >.
* Song F, Bhurke SP, Hooper L, Loke YK, Ryder JJ, Sutton AJ, et al.,
et al. Extent of publication bias in different categories of
research cohorts: a meta-analysis of empirical studies. /BMC Med Res
Methodol/ 2009; 9: 79.
*
http://www.who.int/bulletin/volumes/91/6/13-122762/en/index.html
[Non-text portions of this message have been removed]
quote :
The effectiveness and safety of newly developed drugs are often viewed
too optimistically.
<http://www.who.
^2 <http://www.who.
According to a Cochrane systematic review published recently, new drugs
are seldom found to be substantially better than existing treatments.^
<http://www.who.
However, because of lack of full and transparent access to the protocols
of many clinical trials, compounded by publication bias and selective
reporting of their findings, the true effectiveness of many drugs
remains unknown. It is a fact that the results of trials are more likely
to be published if the findings are favourable than if they are not.^4
<http://www.who.
Independent drug bulletins to promote the prescription of appropriate
drugs: a necessary but difficult task
Bernard Burnand ^a
a. Institute of Social and Preventive Medicine, Lausanne University
Hospital, 10 route de la Corniche, 1010 Lausanne, Switzerland.
Correspondence to Bernard Burnand (e-mail: Bernard.Burnand@
<mailto:Bernard.Burnand@
/Bulletin of the World Health Organization/ 2013;91:391-
http://dx.doi.
Drug treatments constitute a substantial portion of all health-care
interventions. Despite their notable benefits, however, drug treatments
are beyond the reach of sizable population groups and in some parts of
the world there is little access to safe and effective medications even
though new drugs are constantly being developed.
The effectiveness and safety of newly developed drugs are often viewed
too optimistically.
<http://www.who.
^2 <http://www.who.
According to a Cochrane systematic review published recently, new drugs
are seldom found to be substantially better than existing treatments.^
<http://www.who.
However, because of lack of full and transparent access to the protocols
of many clinical trials, compounded by publication bias and selective
reporting of their findings, the true effectiveness of many drugs
remains unknown. It is a fact that the results of trials are more likely
to be published if the findings are favourable than if they are not.^4
<http://www.who.
addition, some measured outcomes are never reported,^5
<http://www.who.
which generally results in an overestimation of effectiveness and an
underestimation of harmful effects. Thus, researchers and the public
only come to know about those findings that are published and disclosed,
and physicians prescribe treatments on the basis of this biased
information. For all of these reasons, it is critically important that
prescribing physicians have a source of information about drug
effectiveness that is independent and as objective as possible.
Truly independent drug bulletins -- those produced without financial or
editorial intervention from the pharmaceutical industry, regulatory
agencies and governments -- are such a source.^6
<http://www.who.
They make a contribution to society by objectively comparing the
effectiveness of different drugs. Independent drug bulletins began to
appear in the 1960s, after the thalidomide scandal. At the time the
pharmaceutical industry was producing new drugs that were modifying
health-care practices. In the 1970s, a group of physicians and
pharmacists in France began to meet to discuss and prepare independent
information about drugs for other physicians and pharmacists. The group,
which came to be known as "Prescrire&quo
1980, when the French Minister of Health commissioned it to provide
independent information to the drug authorities. The group was initially
supported through government funding, but this was eventually suspended
and its drug bulletin, /Prescrire/, has been fully independent since
1993.^7
<http://www.who.
/Prescire/ is an example of a truly independent drug bulletin. It
publishes no advertisements and is financed solely through subscriptions
and training courses for health-care professionals. Its readership,
mainly physicians and pharmacists living in France, grew gradually until
2000, plateaued for several years, and jumped to about 35 000 in 2012
after the European Medicines Agency recommended the withdrawal of
benfluorex.^
<http://www.who.
/Prescrire/ is published in French, although some reports are available
in English.
/Prescrire/&#
among physicians and pharmacists. They are prepared by about 100 paid
collaborators trained in the use of evidence-based approaches and have
no individual authors. This 80-page, entertaining monthly bulletin
contains reports, news and practical guidance. Each report is written by
a main author and a co-author, who together conduct an exhaustive,
systematic search of the information available on a given drug (i.e.
published articles, reviews and guidelines, agency reports, reports
obtained from pharmaceutical companies) and prepare a critical
appraisal. After the co-authors and the editor in charge have reached
agreement on a final draft, every report is reviewed by 15 to 40
internal and external peers before being revised and finalized by the
authors and the bulletin'
including the annual financial statement, are available on the
bulletin'
decisions and daily drug use in France.
There is a definite place for independent drug bulletins.^6
<http://www.who.
The International Society of Drug Bulletins lists 50 of these
publications, mainly from Europe and South America.^9
<http://www.who.
Regardless of the difficulty of relying solely on subscriptions to pay
for the collaborators&#
reproduced. Yet despite their vital role, independent drug bulletins
cannot begin to compensate for the lack of transparency in the reporting
of clinical research.^10
<http://www.who.
Of all the clinical trials that are conducted, only about half publish
their results and those that yield positive findings are selectively
published more often.^11
<http://www.who.
This is inadmissible. Everything from the key components of the protocol
to the full data set must be made available for public scrutiny. To
achieve this goal, authorities as well as national and international
agencies must be persuaded, through strong and persistent advocacy, to
adopt and enforce measures mandating the transparency of the entire
clinical research process.
------------
Acknowledgements
The author thanks Pierre Chirac of "Prescrire&quo
provided.
References
* Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R.
Selective publication of antidepressant trials and its influence on
apparent efficacy. /N Engl J Med/ 2008; 358: 252-60
http://dx.doi.
<http://www.ncbi.
* Rising K, Bacchetti P, Bero L. Reporting bias in drug trials
submitted to the Food and Drug Administration: review of publication
and presentation. /PLoS Med/ 2008; 5: e217, discussion e217
http://dx.doi.
<http://www.ncbi.
* Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, et
al., et al. New treatments compared to established treatments in
randomized trials. /Cochrane Database Syst Rev/ 2012; 10: MR000024
http://dx.doi.
<http://www.ncbi.
* Gøtzsche PC. Why we need easy access to all data from all clinical
trials and how to accomplish it. /Trials/ 2011; 12: 249
http://dx.doi.
<http://www.ncbi.
* Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in
industry-sponsored trials of gabapentin for off-label use. /N Engl J
Med/ 2009; 361: 1963-71 http://dx.doi.
pmid: 19907043
<http://www.ncbi.
* The future of independent drug bulletins. /Drug Ther Bull/ 2012; 50:
61 http://dx.doi.
<http://www.ncbi.
* Prescrire.org [Internet]. /Prescrire./ Paris: Prescrire; 2013.
Available from: http://www.prescrir
* Mullard A. Mediator scandal rocks French medical community. /Lancet/
2011; 377: 890-2 http://dx.doi.
<http://dx.doi.
<http://www.ncbi.
* ISDB [Internet]. Paris: International Society of Drug Bulletins;
2013. Available from: www.isdbweb.
[accessed 25 April 2013].
* Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical
trials. /BMJ/ 2012; 345: e8522 http://dx.doi.
pmid: 23258926
<http://www.ncbi.
* Song F, Bhurke SP, Hooper L, Loke YK, Ryder JJ, Sutton AJ, et al.,
et al. Extent of publication bias in different categories of
research cohorts: a meta-analysis of empirical studies. /BMC Med Res
Methodol/ 2009; 9: 79.
*
http://www.who.
[Non-text portions of this message have been removed]
Mon Jun 3, 2013 11:28 pm (PDT) . Posted by:
"cynthia" cynth.sehat
Cb cek ke mayo clinic symptom checker mba... Sori jg gak bs bny bantu...
.
.
Mon Jun 3, 2013 11:38 pm (PDT) . Posted by:
"Emaknya Najma" emaknya_najma
Selamat siang,
saya sedang hamil 11 minggu, dan saya mengalami furunkle,
amankah jika saya mengkonsumsi asam mefenamat, krn bisulnya nyeri banget.
terima kasih sebelumnya.
Best Regards,
Melly@Mellonezia
[Non-text portions of this message have been removed]
saya sedang hamil 11 minggu, dan saya mengalami furunkle,
amankah jika saya mengkonsumsi asam mefenamat, krn bisulnya nyeri banget.
terima kasih sebelumnya.
Best Regards,
Melly@Mellonezia
[Non-text portions of this message have been removed]
Tue Jun 4, 2013 12:19 am (PDT) . Posted by:
amianakbinus
Alo mba melly
Bs gunakan paracetamol utk obat analgesiknya. Kompres dingin jg membantu menyamankan.
Sdh googling soal "boils" ? Brgkali bs membantu utk home treatmentnya ya.
Cmiiw all
Your BFF,
Ami
Breastfeeding Friends-Klasi YOP
Stop judging, start supporting
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
Bs gunakan paracetamol utk obat analgesiknya. Kompres dingin jg membantu menyamankan.
Sdh googling soal "boils" ? Brgkali bs membantu utk home treatmentnya ya.
Cmiiw all
Your BFF,
Ami
Breastfeeding Friends-Klasi YOP
Stop judging, start supporting
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
Tue Jun 4, 2013 12:37 am (PDT) . Posted by:
"Emaknya Najma" emaknya_najma
Halo mba Ami,
udah googling mba, segala treatment udah dijalani,
tapi entah knp balik lagi balik lagi. keroyokan lagi.
yg sekarang kepikiran adalah mau lab untuk pus nya itu apa betul krn bakteri stapyloccocus.
sebelum hamil sempat mengkonsumsi Ab sesuai resep dokter.
dan sempat berhenti selama bebrapa waktu, tapi setelah itu muncul lagi,
cuma kondisinya sekrg bisulnya sudah gak keroyokan lagi seperti dulu, dan gak segede seprti sebelumnya.
pernah ke dokter untuk drainage pus nya, dan treatment sesuai petunjuk dokter dan hasil gooling.
ternyata masih muncul juga. ini sudah berlangsung selama berbulan2.
untuk analgesik, terima kasih sarannya, jadi lebih baik parcet aja ya.
thanks.
Best Regards,
Melly@Mellonezia
[Non-text portions of this message have been removed]
udah googling mba, segala treatment udah dijalani,
tapi entah knp balik lagi balik lagi. keroyokan lagi.
yg sekarang kepikiran adalah mau lab untuk pus nya itu apa betul krn bakteri stapyloccocus.
sebelum hamil sempat mengkonsumsi Ab sesuai resep dokter.
dan sempat berhenti selama bebrapa waktu, tapi setelah itu muncul lagi,
cuma kondisinya sekrg bisulnya sudah gak keroyokan lagi seperti dulu, dan gak segede seprti sebelumnya.
pernah ke dokter untuk drainage pus nya, dan treatment sesuai petunjuk dokter dan hasil gooling.
ternyata masih muncul juga. ini sudah berlangsung selama berbulan2.
untuk analgesik, terima kasih sarannya, jadi lebih baik parcet aja ya.
thanks.
Best Regards,
Melly@Mellonezia
[Non-text portions of this message have been removed]
Mon Jun 3, 2013 11:47 pm (PDT) . Posted by:
"Astri Desianti" astri.desianti
Share jg,
Saya jg udh skitar 2 taun pake merk p**e *t ... cm sy g berani pake air yg lgs dr keran.jd pake air galon isi ulang deket rumah trus d masukin k pu*e *it ini..soalnya galon bermerk mahal sekali d pulau ini.. 1 galon dapet 35rb..sedangkan drumah bs 2 hr 1 galon.. *irit..hihi.,,,
So far sih g ada pengalaman sakit perut,.tp apa cm sakit perut tanda air layak konsumsi?jd ikut degdeg-an sih pake air ini trlebih anak ikut minum.,gpp kah? *balik nanya hehe
Sent from Yahoo! Mail on Android
[Non-text portions of this message have been removed]
Saya jg udh skitar 2 taun pake merk p**e *t ... cm sy g berani pake air yg lgs dr keran.jd pake air galon isi ulang deket rumah trus d masukin k pu*e *it ini..soalnya galon bermerk mahal sekali d pulau ini.. 1 galon dapet 35rb..sedangkan drumah bs 2 hr 1 galon.. *irit..hihi.
So far sih g ada pengalaman sakit perut,.tp apa cm sakit perut tanda air layak konsumsi?jd ikut degdeg-an sih pake air ini trlebih anak ikut minum.,gpp kah? *balik nanya hehe
Sent from Yahoo! Mail on Android
[Non-text portions of this message have been removed]
Mon Jun 3, 2013 11:52 pm (PDT) . Posted by:
"Erna Wibowo"
Dear SP n Dokter's
Hari ini kheynat 23 bulan sya bawa ke klinik Tumbang RS Harkit, dengan diagnosa Global Delayed n di oleh2i reSep neurotan, folic acid, vit E, pirimox maaf kalo salah penulisan karena agak susah di baca, resep blum saya tebus
Mohon bantuannya adakah link tentang Global delayed yg bisa saya baca, dan juga mengenai vitamin2 tsb perlukah utk kondisi anak saya?
Terima kasih sebelumnya
Erna Wibowo | Duo Khey's Mom
Hari ini kheynat 23 bulan sya bawa ke klinik Tumbang RS Harkit, dengan diagnosa Global Delayed n di oleh2i reSep neurotan, folic acid, vit E, pirimox maaf kalo salah penulisan karena agak susah di baca, resep blum saya tebus
Mohon bantuannya adakah link tentang Global delayed yg bisa saya baca, dan juga mengenai vitamin2 tsb perlukah utk kondisi anak saya?
Terima kasih sebelumnya
Erna Wibowo | Duo Khey's Mom
Mon Jun 3, 2013 11:56 pm (PDT) . Posted by:
"Mama Sheera" mamasheera
Siang Mbak erna
Bisa di search di mayoclinic mbak ttg global delayed nya.
Utk kandungan obatnya aman ato g bisa di search di drugs.com dg mengetikkan kandungan aktif dr obat2nya..
Syafakallah..
Bisa di search di mayoclinic mbak ttg global delayed nya.
Utk kandungan obatnya aman ato g bisa di search di drugs.com dg mengetikkan kandungan aktif dr obat2nya..
Syafakallah.
Tue Jun 4, 2013 12:24 am (PDT) . Posted by:
"Erna Wibowo"
Terima kasih respond nya mama sheera, nnt kalo sdh sampai rumah saya coba googling
Erna Wibowo | Duo Khey's Mom
Erna Wibowo | Duo Khey's Mom
Mon Jun 3, 2013 11:53 pm (PDT) . Posted by:
"Mama Sheera" mamasheera
Siang SPs and doctors.. :)
Hari ini, sheera imunisasi DPT/HB 1, umur sheera 3m asix. Kemarin blm dpt karna habis.
Untuk imunisasi DPT ini kan biasanya ada demam sehingga kadang membuat anak rewel. Tadi disarankan petugas posyandu utk memberikan parcet bila demam dan dikompres juga.
Kalau berdasarkan literatur HT demam, parcet diberikan bila panas >38c dan anak rewel itupun setelah dikompres air hangat msh ttp rewel.
Kl berdasarkn anjuran staff td, kl demam berikan parcet. Itu bagaimana?
Kalau sheera tidak demam tapi rewel, bagaimana cara menyamankannya? Untuk saat ini, sheera mau nya digendong terus, alhamdulillah dia tenang kalau digendong. digendong saja cukup kan? Kalau sheera masih rewel apa yang saya lakukan utk menyamankannya?
Mohon share dan ilmunya, karna ingin memastikan tindakan yg benar seperti apa, saya kuatir panik dan mengambil tindakan yg kurang tepat misalnya memberikan parcet pdhl tdk demam. Mohon maaf bila pertanyaan saya seperti diulang2. Butuh support dr SPs dan doctors sekalian
Terima kasih
Lidya, mama sheera
*gendong sheera sambil jalan2 muterin rumah > ga dibolehin sheera buat duduk :(
Hari ini, sheera imunisasi DPT/HB 1, umur sheera 3m asix. Kemarin blm dpt karna habis.
Untuk imunisasi DPT ini kan biasanya ada demam sehingga kadang membuat anak rewel. Tadi disarankan petugas posyandu utk memberikan parcet bila demam dan dikompres juga.
Kalau berdasarkan literatur HT demam, parcet diberikan bila panas >38c dan anak rewel itupun setelah dikompres air hangat msh ttp rewel.
Kl berdasarkn anjuran staff td, kl demam berikan parcet. Itu bagaimana?
Kalau sheera tidak demam tapi rewel, bagaimana cara menyamankannya? Untuk saat ini, sheera mau nya digendong terus, alhamdulillah dia tenang kalau digendong. digendong saja cukup kan? Kalau sheera masih rewel apa yang saya lakukan utk menyamankannya?
Mohon share dan ilmunya, karna ingin memastikan tindakan yg benar seperti apa, saya kuatir panik dan mengambil tindakan yg kurang tepat misalnya memberikan parcet pdhl tdk demam. Mohon maaf bila pertanyaan saya seperti diulang2. Butuh support dr SPs dan doctors sekalian
Terima kasih
Lidya, mama sheera
*gendong sheera sambil jalan2 muterin rumah > ga dibolehin sheera buat duduk :(
Tue Jun 4, 2013 12:17 am (PDT) . Posted by:
amianakbinus
Alo mba lidya
Dinyamankan maunya anak aj gmn, mauny dgendong yo wes digendong..
And yes, no need parcet kok.. :)
Cmiiw all
Your BFF,
Ami
Breastfeeding Friends-Klasi YOP
Stop judging, start supporting
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
Dinyamankan maunya anak aj gmn, mauny dgendong yo wes digendong..
And yes, no need parcet kok.. :)
Cmiiw all
Your BFF,
Ami
Breastfeeding Friends-Klasi YOP
Stop judging, start supporting
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
GROUP FOOTER MESSAGE
Milis SEHAT mengucapkan terima kasih kepada HANSAPLAST selaku sponsor kegiatan PESAT Balikpapan (4-5 Mei 2013), PESAT SUA Bali (18-19 Mei 2013), dan PESAT SUA Bandung, Juni 2013.
Hansaplast, "Sembuh Lebih Cepat, Ceria Setiap Saat"
Terima kasih & penghargaan sedalam-dalamnya kepada HBTLaw dan PT.Intiland yang telah dan konsisten mensponsori program kami, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"Milis SEHAT didukung oleh : CBN Net Internet Access & Website.
=================================================================
Milis Sehat thanks to HANSAPLAST as sponsor for PESAT Balikpapan (May 4-5, 2013), PESAT SUA Bali (May 18-19, 2013), dan PESAT SUA Bandung in June 2013.
Hansaplast, "Sembuh Lebih Cepat, Ceria Setiap Saat"
Our biggest gratitude to HBTLaw and PT. Intiland, who have consistently sponsored our program, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"SEHAT mailing list is supported by CBN Net for Internet Access &Website.
Kunjungi kami di (Visit us at):
Official Web : http://milissehat.web.id/
FB : http://www.facebook.com/pages/Milissehat/131922690207238
Twitter : @milissehat <http://twitter.com/milissehat/>
==================================================================
Donasi (donation):
Rekening Yayasan Orang Tua Peduli
Bank Mandiri
Cabang Kemang Raya Jakarta
Account Number: 126.000.4634514
==================================================================
Hansaplast, "Sembuh Lebih Cepat, Ceria Setiap Saat"
Terima kasih & penghargaan sedalam-dalamnya kepada HBTLaw dan PT.Intiland yang telah dan konsisten mensponsori program kami, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"Milis SEHAT didukung oleh : CBN Net Internet Access & Website.
=================================================================
Milis Sehat thanks to HANSAPLAST as sponsor for PESAT Balikpapan (May 4-5, 2013), PESAT SUA Bali (May 18-19, 2013), dan PESAT SUA Bandung in June 2013.
Hansaplast, "Sembuh Lebih Cepat, Ceria Setiap Saat"
Our biggest gratitude to HBTLaw and PT. Intiland, who have consistently sponsored our program, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"SEHAT mailing list is supported by CBN Net for Internet Access &Website.
Kunjungi kami di (Visit us at):
Official Web : http://milissehat.web.id/
FB : http://www.facebook.com/pages/Milissehat/131922690207238
Twitter : @milissehat <http://twitter.com/milissehat/>
==================================================================
Donasi (donation):
Rekening Yayasan Orang Tua Peduli
Bank Mandiri
Cabang Kemang Raya Jakarta
Account Number: 126.000.4634514
==================================================================